The Cancer Stakeholder Alliance Working Group is composed of CSA members from different charities and non-government organizations from across Canada and representing a variety of cancer indications and operational interests, as well as members of the BioCanRx Leadership and Administration team.
The Working Group is tasked with making joint CSA and BioCanRx priorities a reality.
The CSA members of the Working Group also make decisions and recommendations on behalf of the CSA to the BioCanRx Leadership, Research Management Committee and Board of Directors.
Membership is on an annual basis. Please contact Stéphanie Michaud, by email (smichaud@biocanrx.com) for more information or to join.
MEMBERS OF THE CSA WORKING GROUP:
In 2012, he was diagnosed with multiple myeloma, an incurable hematologic cancer. Since then, David has had two stem cell transplants and a variety of other treatments, including participation in a phase 1 clinical trial. Since his diagnosis, he has become very active with Myeloma Canada, a successful patient-based charitable organization, in various patient support, education, advocacy, research, awareness, and fundraising activities. He is also active on several myeloma patient support groups in southern Ontario, including his role as long-term chair of the Toronto and District Multiple Myeloma Support Group. David is the founding chair of the nation-wide Myeloma Canada Patient Advisory Council, where he was an ex-officio member of the Board of Directors.
Since 2015, he’s been an active Patient Representative in the Cancer Clinical Trials Group, in the Hematology Disease Site Committee, and previously in the Quality of Life Committee and Melanoma Disease Site Committee. David is also a member of the CADTH Patient and Community Advisory Committee.
David has a strong interest in treatment research and feels privileged to know many hundreds of myeloma patients across Canada.
Inspired by his grandmother’s blood cancer journey, Dr. O’Connell first became involved in research as a way to find new and better ways to manage the disease.
At LLSC, Dr. O’Connell leads the organization’s research funding program and provides support to existing and prospective stakeholders. He aims strengthen the current framework, broaden the scope of research partnerships and diversify or grow the research portfolio so that the LLSC is at the forefront of blood cancer research in Canada. He works closely with the research community to help connect constituents to the incredible, and potentially, life-saving research that is being done across the country.
Over the years, I have had the occasion to observe the health system from different perspectives. The combination of both professional and personal experiences makes me today, more aware than ever of the latent potential which lies at the heart of a real partnership between the different actors of the health system: I have the faith that by introducing such a collaboration, there is a way to better care, better costs, and better satisfaction for everyone involved in the process. Contributing to the advancement of the patient-partnership in research makes senses out of a disease I suffered from, that had none. It is like having the chance to transform the citrus life handed me into a nice lemonade.
MEMBERS OF BIOCANRX:
Nancy Boyle Director of Communications, Marketing & Engagement BioCanRx |
Laurie Cameron Manager, Knowledge Mobilization & Operations BioCanRx |
Megan Mahoney Director, Scientific Affairs and Training Programs BioCanRx |
Stéphanie Michaud President & CEO BioCanRx |
Jennifer Quizi Director, Biotherapeutics Manufacturing Operations BioCanRx |